Capsul Desk writes each daily edition. We are senior reporters and editors from Norstella's News and Insights division, with decades covering the industry's full arc, from a molecule's first trial to the pricing fight that decides who can afford it.
Christophe Weber leaves a global top-ten drugmaker, and the debt it took to get there. The verdict now belongs to the executive who arrived in the very transaction that made it.
The convention opens with the FDA short of leaders, while Europe's new drug-vetting system stumbles on its first attempt.
A cluster of recent deals put AI discovery platforms at the center. The terms, optioned and hedged, are more cautious than the conviction suggests.
Obesity just went from the 30th most-studied disease to the 2nd in three years, and almost the entire bet is riding on a single class of drugs.
Sponsors keep misreading red flags for green, yet the traits FDA actually falls for are predictable enough to plan a whole program around.
GSK spends $10.6bn to outrun a patent cliff while the Pentagon quietly reprices the supply chain underneath everyone. Two different bets on the same question: what is access actually worth.
Cutting headcount to survive the next milestone creates exposures distinct from those of growth, and most boards underestimate them.
ASCO ended a week ago. The filing and the deal structure that deserve a closer look.
Bundibugyo had no vaccine, no treatment, no diagnostic for seventeen years. It took 900 cases to change the math.
Two qualify as first-in-class among 2032's ten biggest oncology bets. So why is big pharma paying nine figures for assets that haven't read out?
